Merck presents first phase 3 data in Japanese patients for omarigliptin
Merck announced data from the Phase 3 clinical development program for omarigliptin, Merck’s investigational once-weekly DPP-4 inhibitor for treatment of type 2 diabetes. In Japanese patients, omarigliptin provided comparable efficacy and tolerability to Merck’s once-daily DPP-4 inhibitor JANUVIA®. September 17, 2014